Alpha Tau Medical (NASDAQ:DRTS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a research note released on Friday,Benzinga reports. They currently have a $9.00 price target on the stock.

Separately, Piper Sandler reissued an “overweight” rating and set a $7.00 price objective on shares of Alpha Tau Medical in a report on Thursday, August 15th.

Alpha Tau Medical Price Performance

Shares of NASDAQ:DRTS opened at $2.53 on Friday. The firm has a 50 day simple moving average of $2.29 and a 200 day simple moving average of $2.30. The company has a market cap of $176.23 million, a price-to-earnings ratio of -5.88 and a beta of 0.77. Alpha Tau Medical has a one year low of $1.75 and a one year high of $3.40. The company has a debt-to-equity ratio of 0.08, a current ratio of 10.99 and a quick ratio of 11.60.

Hedge Funds Weigh In On Alpha Tau Medical

Several large investors have recently modified their holdings of the business. Levin Capital Strategies L.P. grew its position in shares of Alpha Tau Medical by 2.6% in the 1st quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock valued at $999,000 after buying an additional 8,641 shares during the last quarter. Financial Guidance Group Inc. lifted its stake in shares of Alpha Tau Medical by 83.7% in the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares during the period. Aptus Capital Advisors LLC boosted its holdings in Alpha Tau Medical by 83.7% in the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock valued at $56,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Caprock Group LLC bought a new stake in Alpha Tau Medical in the second quarter valued at approximately $59,000. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.